Valuation : Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Market Cap 13.23B 1.97B 1.7B 1.6B 1.46B 2.73B 186B 2.75B 18.95B 7.35B 95.1B 7.39B 7.23B 312B P/E 2026 *
17.2x
P/E 2027 * 14.7x
Enterprise Value 11.81B 1.76B 1.52B 1.43B 1.3B 2.43B 166B 2.45B 16.9B 6.56B 84.85B 6.6B 6.45B 279B EV / Sales 2026 *
2.04x
EV / Sales 2027 * 2.22x
Free-Float
14.33%
Yield 2026 *
0.7%
Yield 2027 * 0.8%
29/08 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
26/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Ordinary Final Dividend on A Shares for the Year Ended December 31, 2025, Payable on 18 June 2026 CI
23/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Board Changes CI
30/04 Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1 MT
29/04 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
31/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2025, Payable on 22 July 2026 CI
31/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025 MT
16/12 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves the Election of Pu Hong as Independent Non-Executive Director, Effective December 16, 2025 CI
24/11 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Retirement of Chuan Lu from the Board CI
31/10/25 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
30/08/25 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day-1.09%
1 week-3.30%
Current month-0.70%
1 month+2.89%
3 months-0.30%
6 months-17.05%
Current year-15.44%
1 week 9.91
Extreme 9.91
10.6
1 month 9.57
Extreme 9.57
11.57
Current year 8.5
Extreme 8.5
12.64
1 year 8.5
Extreme 8.5
13.33
3 years 6.89
Extreme 6.89
14.34
5 years 6.89
Extreme 6.89
18.89
10 years 6.89
Extreme 6.89
30.69
Manager TitleAgeSince
Chief Executive Officer 65 21/04/1998
Corporate Officer/Principal 61 21/04/1998
Director of Finance/CFO 51 21/08/2023
Director TitleAgeSince
Director/Board Member 61 21/04/1998
Chairman 62 21/04/1998
Director/Board Member 65 21/04/1998
Date Insider Type Main position Quantity % Market Cap. Importance
23/5/23 Sell 11,200 0.0009%
26/5/21 Other

Chief Financial Officer

459,588 0.2088%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-3.30%-24.36%-15.15% 1.99B
+0.01%-2.47%+57.79%+108.23% 1,034B
+1.48%+1.93%+54.56%+71.49% 654B
+0.67%-0.45%+23.50%+76.60% 459B
+0.49%-6.58%+34.20%+34.59% 343B
+0.27%+2.32%+29.33%+46.97% 307B
+0.12%-4.01%+1.06%+11.93% 251B
+1.08%+0.14%+53.92%+72.51% 237B
+2.64%-2.00%-17.38%-53.64% 202B
-0.21%+0.56%+32.43%+95.19% 186B
Average +0.55%-1.42%+24.51%+44.87% 367.36B
Weighted average by Cap. +0.63%-0.48%+38.77%+67.26%

Financials

2026 *2027 *
Net sales 5.78B 859M 741M 698M 636M 1.19B 81.18B 1.2B 8.27B 3.21B 41.51B 3.23B 3.16B 136B 6.27B 934M 805M 759M 691M 1.29B 88.2B 1.3B 8.98B 3.49B 45.09B 3.51B 3.43B 148B
Net income 574M 85.44M 73.71M 69.43M 63.26M 118M 8.07B 119M 822M 319M 4.13B 321M 314M 13.55B 596M 88.74M 76.56M 72.12M 65.71M 123M 8.38B 124M 854M 331M 4.29B 333M 326M 14.08B
Net Debt -1.43B -212M -183M -173M -157M -294M -20.06B -296M -2.04B -793M -10.25B -797M -780M -33.69B 668M 99.36M 85.71M 80.74M 73.57M 138M 9.39B 139M 956M 371M 4.8B 373M 365M 15.76B
Logo Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The Company operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The Company conducts its business in the domestic and overseas markets.
Employees
2,150
Date Price Change Volume
02/09/26 CNY 9.970 -1.09% 4,488,328
01/09/26 CNY 10.08 +0.40% 5,827,285
31/08/26 CNY 10.04 -3.92% 7,688,460
28/08/26 CNY 10.45 -1.42% 5,347,000
27/08/26 CNY 10.60 +1.92% 6,685,978
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.970CNY
Average target price
8.500CNY
Spread / Average Target
-14.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002399 Stock